DIAN Data Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-D1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 31 - 40 of 295

Investigator:Cyril Pottier

Title:Modifiers of Alzheimer's disease: a genetic approach

Date of Request:04/28/2023



Aim 1:To identify genetic modifiers of disease presentation in PSEN1 mutation carriers

Investigator:Dr. Tallulah Andrews

Title:Single-nucleus RNAseq of a humanized mouse model of Alzheimer's disease

Date of Request:04/24/2023

Status:pending approval

ID:DIAN- D2309

Aim 1:Generate a novel humanized mouse model of AD with disease variants in APP and APOE genes.

Aim 2:Perform deep behavioural and molecular phenotyping of the mouse model

Aim 3:Perform snRNAseq of multiple brain regions of mouse model and compare to human snRNAseq from patients with AD

Investigator:Nelly Joseph-Mathurin

Title:Evaluation of the neurovascular unit in the setting of pathogenesis and treatment of autosomal dominant Alzheimer disease

Date of Request:04/21/2023



Aim 1:Perform proteomic characterization of NVU disruption and develop imaging markers of vascular changes in ADAD.

Aim 2:Determine the trajectories of NVU disruption markers and their relation to the pattern of disease progression in ADAD.

Aim 3:Examine influence of NVU disruption on drug efficacy and safety outcome measures in ADAD.

Investigator:Randall J Bateman

Title:Biomarker progression modeling in autosomal-dominant Alzheimer’s disease and implications for clinical trial design

Date of Request:04/21/2023



Aim 1:Modeling biomarker progression in the DIAN population

Aim 2:Using biomarker progression modeling to inform clinical trial design

Investigator:Dr. Eric M McDade

Title:Drug Dose Modeling for potential inclusion in the DIAN-TU 002 trial

Date of Request:04/04/2023



Aim 1:Conduct dose modeling projections for the patient population of interest in the study to determine dose selection and sample size.

Investigator:Dr Sarah Bauermeister

Title:Biopsychosocial determinants of cognitive and biomarker trajectories in preclinical Alzheimer's disease

Date of Request:03/23/2023

Status:pending review


Aim 1:The first objective is to characterise the biopsychosocial determinants of AD across modifiable and non-modifiable factors throughout the lifespan across multiple cohorts including Memento, DIAN, WRAP, ADNI, BIOCARD, SMC amyloid, and other DPUK databases. The latent constructs, which have not previously been examined in such extensive detail, include physical health, mental health, diet, family history, sex, ethnicity, education, sociality, life functionality, employment, and traumatic brain injury.

Aim 2:The second objective is to explore an AD prediction model utilising PET amyloid data, building on objective 1. Designed utilising the significant constructs, the hypothesis is that this novel disease model will predict preclinical AD with relative accuracy in patient populations to facilitate earlier and more accurate disease diagnoses .

Aim 3:The third objective is to investigate the relationship between the biopsychosocial determinants included in the disease prediction model and structural brain changes (MRI). Utilising the BHC and healthy control cohorts, the study hypothesises that there will be a significant difference in health/lifestyle outcomes between the two populations as well as a significant relationship between these outcomes and level of cognitive/structural impairment, thus strengthening the role of biopsychosocial determinants in disease trajetory

Investigator:Prof Ralph Martins

Title:Temporal ordering of plasma biomarkers and their association with amyloid pathology, cerebral atrophy, cerebral metabolism and cognition in autosomal dominant Alzheimer’s disease

Date of Request:03/08/2023



Aim 1:Investigate the temporal order of AD-related plasma biomarker (abeta42/40 ratio, p-tau181, GFAP and NFL) divergence between ADAD mutation carriers and non-carriers as a function of EYO.

Aim 2:Investigate the association of AD-related plasma biomarkers with Aβ pathology (PiB-PET) and ADAD severity (CDR global) in mutation carriers.

Aim 3:Investigate the cross-sectional association of plasma biomarkers with neurodegeneration (hippocampal volume and precuneus thickness), cognition (MMSE, CDR-SB and composite cognition score) and cerebral metabolism (FDG-PET).

Aim 4Association of plasma biomarkers with subsequent neurodegeneration, cognitive decline, cerebral hypometabolism.

Investigator:Ben Handen

Title:Comparison of plasma NfL in ABC-DS and DIAN

Date of Request:03/03/2023

Status:pending review


Aim 1:Compare plasma NfL in ABC-DS and DIAN as a function of brain structure

Aim 2:Examine how plasma NfL and brain structure vary based on DIAN mutation type and location

Investigator:Chia-Ling Phuah

Title:WMH Spatial Patterns in ADAD

Date of Request:02/21/2023



Aim 1:Evaluate for difference(s) in WMH topographical distributions between AD and CAA

Investigator:Randall J. Bateman

Title:DIAN OBS Data for the DIAN-TU OLE

Date of Request:01/31/2023



Aim 1:Identify participant data to use as external controls for the DIAN-TU OLE

Aim 2:Pull the selected data and analyze as external controls for the DIAN-TU OLE.